| Trial | Updated / Type |
Status | Phase | Were Results Reported |
Reported Actual Enrollment |
(MeSH) Terms |
Why Stopped
Limitations And Caveats |
Annotator decisions |
|---|---|---|---|---|---|---|---|---|
| NCT03294252 Details | 2022-04-25 Interventional | 1/2 | 34 | Fluorouracil Folic Acid Leucovorin Levoleucovorin Oxaliplatin Gastrointestina… Neoplasm Metast… Digestive Cance… | The 34 patients included had all completed their treatment period under the protocol and the
data could be collected to assess the main objective and the secondary objectives before the
last theoretical follow-up. - | |||
| NCT03148756 Details | 2022-04-25 Interventional | 2 | 2 | Dalbavancin Bacteremia Endocarditis Endocarditis, B… | Study stopped due to business reasons. - | |||
| NCT05157997 Details | 2022-04-22 Interventional | 1 | 0 | Antibodies Casirivimab and… COVID-19 Organ Transplan… | New information regarding COVID-19 - | |||
| NCT04369742 Details | 2022-04-22 Interventional | 2 | 128 | Calcium Hydroxychloroqu… COVID-19 | Investigator decision - | |||
| NCT03364686 Details | 2022-04-21 Interventional | 2 | 6 | Biotin Healthy Volunte… | Due to enrollment challenges related to COVID and lack of coordinator support The clinical trial was terminated early due to challenges with enrollment and lack of study coordinator support. Early termination leading to small numbers of subjects analyzed. | |||
| NCT02937766 Details | 2022-04-21 Interventional | 3 | 60 | 11-hydroxyproge… 17 alpha-Hydrox… Assessing Injec… | The Sponsor elected to discontinue the study prematurely due to business reasons The Sponsor elected to discontinue the study prematurely due to business reasons. The only parameters analyzed for efficacy were Ease of Drug Preparation and Ease of Injection Technique. | |||
| NCT02927938 Details | 2022-04-21 Interventional | 3 | 18 | Cytarabine Leukemia Leukemia, Myelo… Leukemia, Myelo… Acute Myeloid L… | Study terminated 7/23/2019 due to limited participation and testing challenges. - | |||
| NCT02719392 Details | 2022-04-21 Interventional | 4 | - | Acetylcysteine Minocycline N-monoacetylcys… Bipolar Disorde… Depression Depressive Diso… Bipolar Depress… | Due to limited study staff and the COVID-19 pandemic, enrollment has been paused as staff hours
for this project have been reduced and reallocated to other projects. - | |||
| NCT04371952 Details | 2022-04-20 Interventional | 3 | 0 | Doxycycline COVID-19 COVID19 | withdrawal due to the evolution of the epidemic, the arrival of vaccination and because the
associated centres could no longer commit to the number of inclusions requested - | |||
| NCT03365752 Details | 2022-04-20 Interventional | 2 | 39 | Anesthetics Anesthetics, Ge… Chloroprocaine Mepivacaine Knee Arthroscop… | Study halted due to COVID-19 pandemic and terminated early per request of principal
investigator as Chloroprocaine use in spinal procedures has become incorporated as standard of
care at HSS. This project was terminated early, as enrollment was negatively impacted to due to the COVID-19 pandemic and because clinical practice has shifted to include the use of chloroprocaine in spinal procedures as standard of care at the Hospital for Special Surgery. | |||
| NCT02897050 Details | 2022-04-20 Interventional | 2 | - | Capecitabine Cyclophosphamid… Docetaxel Epirubicin Fluorouracil Breast Neoplasm… Triple Negative… Breast Cancer | - - | |||
| NCT04919096 Details | 2022-04-19 Interventional | 1 | 0 | Aflibercept Macular Degener… Wet Age-related… | Due to an internal decision to prioritise its development pipeline, Clover have decided to
close down study CLO-SCB-420-001. This was a corporate decision and not the results of new data
or information arising related to SCB-420 - | |||
| NCT04388683 Details | 2022-04-19 Interventional | 2 | 10 | Nitric Oxide COVID-19 | Bellerophon requested study to be stopped. The study was terminated early by request of the company providing the iNO Drug. Our data set is small are analysis was effected by this. | |||
| NCT03787251 Details | 2022-04-19 Interventional | 2 | 0 | Apatinib Esophageal Neop… Recurrence | In China, apatinib has been approved as an indication drug for esophageal squamous cell
carcinoma, which makes it very difficult for our clinical trial to enroll patients. We regret
that we failed to implement the design as planned. - | |||
| NCT02588248 Details | 2022-04-19 Interventional | 3 | 82 | Menthol Peppermint oil Colonic Neoplas… Colonic Polyps Colon Cancer | Sponsor/Investigator has decided to close out the study - | |||
| NCT04286529 Details | 2022-04-18 Interventional | 1 | 17 | Calcitriol Prediabetic Sta… Pre-Diabetic | Difficulty with study logistics due to COVID-19 - | |||
| NCT03936192 Details | 2022-04-18 Interventional | 3 | 0 | Meloxicam Osteoarthritis Osteoarthritis,… Knee Osteoarthr… | Company decision - | |||
| NCT04901689 Details | 2022-04-15 Interventional | 3 | - | Leronlimab COVID-19 Pneumonia COVID-19 Pneumo… | Pending DSMB evaluation - | |||
| NCT04901676 Details | 2022-04-15 Interventional | 3 | - | Leronlimab COVID-19 Pneumonia COVID-19 Pneumo… | Pending DSMB evaluation - | |||
| NCT04592991 Details | 2022-04-15 Interventional | 1 | 1 | 1,4,7,10-tetraa… Aneurysm Aortic Aneurysm Aortic Aneurysm… Abdominal Aorti… | We were only able to enroll 1 subject so we had no way to compare a control or other study
groups and develop any kind of results. This study is essentially the same study as
NCT04586452, which we would like to place focus and effort on that study. - |